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Background: STAT is the backward position of cytokine and growth factor receptors in the nucleus, STAT dimers could
bind to DNA and induce transcription of specific target genes. Several lines of evidence support the important roles of
STAT, especially STAT5, in carcinogenesis. The overexpression of STAT 5 is related to the differentiation and apoptosis of
tumor cells. However, the role of STAT5 in esophageal squamous cell carcinoma remains unclear.
Methods: The siRNA vectors aiming to STAT5 gene were constructed. STAT5 siRNA was transfected into Eca-109 cells by
Lipofectamine™2000. Expression of STAT5、Bcl-2 and Cyclin D1 were analyzed by Western blot and RT-PCR. Eca-109
cells proliferation was determined by MTT. Eca-109 cell cycle and apoptosis were detected by the flow cytometry.
Boyden chamber was used to evaluate the invasion and metastasis capabilities of Eca-109 cells.
Results: The double strands oligonucleotide of siRNA aiming to STAT5 was successfully cloned into the pRNAT-U6.1
vector, and the target sequence coincided with the design. RT-PCR and Western blotting detection demonstrated
that the expression levels of STAT5、Bcl-2 and Cyclin D1 gene were obviously decreased in Eca-109 cells transfected
with STAT5 siRNA. STAT5 siRNA could suppress the proliferation of Eca-109 cells. The proportion of S and G2/M
period frequency was significantly decreased (p < 0.05). The proportion of G0/G1 period frequency was significantly
increased (p < 0.05). The average amount of cells penetrating Matrigel was significantly decreased (p < 0.05).
Conclusions: STAT5 silenced by siRNA could induce the apoptosis and suppress the proliferation、invasion and
metastasis of esophageal carcinoma cell line Eca-109, which indicated STAT5 might be a novel therapeutic strategy
for the human ESCC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1351913072103000
Keywords: STAT5, siRNA, Proliferation, Cell cycle, ApoptosisIntroduction
The STAT (signal transducer and activator of transcrip-
tion) family of proteins includes 7 members (STAT −1、
2、3、4、5a、5b and 6) encoded by distinct genes in
mammalian cells. The STAT family members are latent
cytoplasmic transcription factors that are activated in re-
sponse to extracellular signaling proteins, including
growth factors, cytokines, hormones, and peptides [1-5].
STAT is the backward position of cytokine and growth* Correspondence: zangwenqiao@sina.com; zhaogq@126.com
2College of Basic Medical Sciences, Zhengzhou University, Zhengzhou,
People’s Republic of China
Full list of author information is available at the end of the article
© 2013 Yang et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfactor receptors in the nucleus, STAT dimers bind to
DNA and induce transcription of specific target genes
[6-9]. The overexpression of STAT 5 is related to the
differentiation、apoptosis and new capillaries of tumor
cells [10-14]. In this study, We silenced STAT5 by siRNA
to explore the effect on proliferation、apoptosis and inva-
sion of esophageal carcinoma cell line Eca-109, which gave
a certain target in gene therapy of Esophageal Carcinoma.Materials and methods
Main materials
siRNA vectors pRNAT-U6.1/Neo (GeneScript Corp,
China); BamHI 、HindIII and T4 DNA ligase(Promegad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lin D1,GAPDH(Santa Cruz Corp, USA); RPMI 1640;
LipofectAmine™2000, G418(Invitrogen, USA); MTT、
DMSO、Trypsin、PI、RNAase(Sigma Corp, USA);
Esophageal carcinoma cell line Eca-109 were obtained
from the basic medical college of Zhengzhou University.
Design the STAT5 gene target oligonucleotide
Abide by the principle of design siRNA fragment and the
target oligonucleotide was designed with the help of the
GenScript siRNA Target Finder software of GenScript
company, which the following web address provided:
https://www.genscript.com/ssl-bin/app/rnai The target se-
quences located in 2851nt-2869nt (GGCAGTGAGTTTC
GTGAAG).
The construction of siRNA vectors
Two couples of hairpin sample DNA oligonycleotides
(2851-1、2851-2 and Con-1、Con-2)were annealed to
produce dsDNA(siSTAT5 and siCon). Then the dsDNA
was inserted into the BglII and HindIII site of thepRNAT-
U6.1/Neo vector.2 × reaction buffer 5 μL, sticking end lin-
ear pRNAT-U6.1 /Neo vectors 1 μL, T4 DNA ligase 1 μL,
dsDNA(siSTAT5 and siCon)3 μL, All of them were for a
whole night at 4°C. The recombinant vectors were
transformed into Escherichia coli DH5α. The pRNAT-
U6.1/Neo-siSTAT5 and pRNAT-U6.1/Neo-siCon vectors
were constructed after the analyzsis of consequense.
The transfection of Eca-109 cells with
Lipofectamine™2000
When the density of plasmids was 2 μg/ml, the pRNAT-
U6.1/Neo-siSTAT5 and pRNAT-U6.1/Neo-siCon were
transfected into Eca-109 cells, as the experiment














The primers and probes were designed according to the software of Primer Express
company, China.manufacturer’s protocol of Lipofectamine™2000, and the
cells were cultured after 6 h. The experiments were
performed independently four times.
RT-PCR
The GAPDH was used as the internal reference, then the
primers and probes were designed according to the soft-
ware of Primer Express 3.0(ABI Corp), which all are
synthetized by Shanghai bioengineering company (Table 1).
Total RNA was isolated from the cells using Trizol extrac-
tion kit according to the manufacturer’s protocol. RT-PCR
was performed with the apparatus of ABI Step One Plus
PCR. The ratio of the copies of the detected genes
(STAT5、Bcl-2、Cyclin D1)to the copies of GAPDH was
the relative expression quantity. The experiments were
performed independently four times.
Western blot
Cells were lysed for total protein extraction. The protein
concentration was determined by the BCA method
(KeyGEN, China), and 30 μg of protein lysates were
subjected to SDS-PAGE. The electrophoresed proteins
were transferred to nitrocellulose membranes (Whatman,
USA), which were blocked in 5% non-fat milk and
incubated overnight at 4°C with diluted first antibodies.
Membranes were then incubated with HRP-conjugated sec-
ondary antibody (1:2,500, Santa Cruz, USA). After washing
with PBST buffer (PBS containing 0.05% Tween-20), mem-
branes were probed using ultra-enhanced chemilumines-
cence western blotting detection reagents. GAPDH was
used as the internal reference.
MTT assay
The experimental groups of cells in the logarithmic













3.0(ABI Corp), which all were synthetized by Shanghai bioengineering
Table 2 STAT5 siRNA inhibited significantly the mRNA
expression of STAT5、Bcl-2 and Cyclin D1
Group n STAT5/GAPDH Bcl-2/GAPDH Cyclin D1/GAPDH
STAT5 siRNA 4 0.301 ± 0.012* 0.266 ± 0.012* 0.048 ± 0.005*
siRNA control 4 0.836 ± 0.038 0.645 ± 0.023 0.261 ± 0.013
The blank
control
4 0.857 ± 0.041 0.687 ± 0.027 0.273 ± 0.012
Cells were incubated with different synthetic oligonucleotides as described in
the materials and methods section, and STAT5、Bcl-2 and Cyclin D1mRNA
were quantified by real time PCR. The targeted STAT5 siRNA inhibited
significantly the expression of STAT5、Bcl-2 and Cyclin D1 gene (*p <0.05).
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of MTT (5 mg/ml) was added to the corresponding well,
cells were incubated at 37°C for an additional 4 h, and
the reaction was stopped by lysing the cells with 200 μl
of DMSO for 20 min. Optical density was measured at
590 nm The experiments were performed independently
four times.
The flow cytometry detects the cell cycle
For cell cycle analysis by flow cytometry (FCM), cells in
the logarithmic phase of growth were harvested by
trypsinization, washed with PBS, fixed with 75% ethanol
overnight at 4°C and incubated with RNase at 37°C for
30 min. Nuclei were stained with propidium iodide for
30 min. A total of 104 nuclei were examined in a
FACSCalibur Flow Cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA). The experiments were performed inde-
pendently four times.
Cell apoptosis assay
Every group cells were harvested and diluted with PBS
twice. Then 5 μL of FITC-labeled enhanced-annexinV
and 5 μl 20 μg/ml of propidium iodide were added to
100 μl cell . Upon incubation in the dark for 15 min at
room temperature, samples were diluted with 400 μl
PBS. Flow cytometry was carried out on a FACS can in-
strument. The result was analysed by random software.
The experiments were performed independently four
times.
Cell invasion assay
The invasion ability of Eca-109 cells was assayed using
Transwells (8-μm pore size, Corning Costar Corp).
Transwells filters were coated with matrigel (3.9 μg/μl,
60-80 μl) on the upper surface of the polycarbonic mem-
brane (6.5 mm in diameter, 8 μm pore size). Eca-109 cells
(3 × 105) treated with 1640 medium without FBS were
plated to the upper chamber. 1640 medium with the
supernatant of NIH3T3 cells as chemoattractants were
plated in the lower chamber of the 24-well pates. After
incubation for 24 h, noninvading cells were removed
mechanically from the upper chamber using a cotton
swab. Cells that invaded to the lower surface of the
transwell membrane were fixed in methanol for 30 min
at 37°C and stained with 0.05% crystal violet for 1 h. Cells
were quantified by counting the number of stained cells
in five individual fields by microscopy. The experiments
were performed independently four times.
Statistical analysis
SPSS17.0 was used for statistical analysis. One-way ana-
lysis of variance (ANOVA) and the χ2 test were used to
analyze the significance between groups. Multiple com-
parisons between the parental and control vector groupswere made using the Least Significant Difference test
when the probability for ANOVA was statistically signifi-
cant. All data represent mean ± SD. Statistical signifi-
cance was set at p < 0.05.
Results
STAT5 siRNA inhibited significantly the mRNA and protein
expression of STAT5、Bcl-2 and Cyclin D1
The result of RT-PCR was in the Table 1. The STAT5、
Bcl-2 and Cyclin D1 mRNA expression in untransfected
Eca-109 cells were coincident with that in the cells
transfected with control vector( pRNAT-U6.1/Neo-siCon).
The statistical data between them was not significance
(p > 0.05). RT-PCR results showed that STAT5、Bcl-2
and Cyclin D1 mRNA expression in STAT5 siRNA group
were significantly inhibited compared to siRNA control
and blank control group as shown in Table 2. The
targeted STAT5 siRNA inhibited significantly the mRNA
expression of STAT5 gene. The results of Western-Blot
showed the expression of STAT5 protein was signifi-
cantly decreased in Eca-109 cells in STAT5 siRNA group
(Figure 1A). The result showed that the Bcl-2 and Cyclin
D1 expression in Eca-109 cells transfected with STAT5
siRNA vector were significantly decreased.
STAT5 siRNA inhibited esophageal carcinoma cells
proliferation in vitro
Compared with untransfected cells and cells transfected
with control vector, the Eca-109 cell transfected with
vector (pRNAT-U6.1/Neo-siSTAT5) were significantly
depressed respectively at 24 h、48 h and 72 h. The cells
become round at 24h. With the longer time, the smaller
shed cells become more and more. The result showed
that silencing the STAT5 depresses the proliferation of
esophageal carcinoma cell line Eca-109 (Figure 1B).
STAT5 siRNA affect the cell cycle of Eca-109 cells
Compared with untransfected Eca-109 cells and cells
transfected with control vector, The proportion of S and
G2/M period frequency of Eca-109 cell transfected with
vetor (pRNAT-U6.1/Neo-siSTAT5) was significantly de-
creased(p < 0.05). The proportion of G0/G1 period
Figure 1 The results of protein expression and cell proliferation. A STAT5 siRNA inhibited significantly the protein expression of
STAT5、Bcl-2 and Cyclin D1. Cells were incubated with different synthetic oligonucleotides as described in the materials and methods section, and
CXCR4 protein was quantified by Western-Blot. The targeted CXCR4 siRNA inhibited significantly the protein expression of STAT5、Bcl-2 and Cyclin
D1 gene. B cell proliferation was assessed using the MTT assay. Data are presented as the mean of four experiments. Silencing the STAT5 depresses
the proliferation of esophageal carcinoma cell line Eca-109. Significant difference (p <0.05).
Table 4 STAT5 siRNA induced the apoptosis and
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in Table 3.
STAT5 siRNA induced the apoptosis and suppressed
invasion and metastasis of Eca-109
Compared with untransfected Eca-109 cells and cells
transfected with conrtrol vector, The average apoptosis rate
of Eca-109 cell transfected with vector (pRNAT-U6.1/Neo-
siSTAT5) was significantly increased (p < 0.05),The average
amount of cells penetrating matrigel was significantly de-
creased(p < 0.05). The result showed that silencing the
STAT5 induced the apoptosis and suppressed invasion and
metastasis of esophageal carcinoma cell line Eca-109 as
shown in Table 4.
Discussion
The activation of JAK phosphorylates STAT proteins, lead-
ing to their dimerization and translocation into the nucleus
[15]. In the nucleus, STATs act as transcription factors with
pleiotropic downstream effects. STATs are phosphorylated
on tyrosine residues via JAK kinases and on serine residues
by a variety of serine/threonine kinases [16]. STATs thenTable 3 STAT5 siRNA affect the cell cycle of Eca-109 cells
Group G0 ~ G1(%) S(%) G2 ~M(%)
STAT5 siRNA 75.9 ± 2.3 20.85 ± 0.55* 3.25 ± 0.12*
siRNA control 64.23 ± 1.92 27.8 ± 0.61 7.96 ± 0.27
The blank control 64.69 ± 2.16 26.46 ± 0.59 8.85 ± 0.31
The cell cycle was detected by flow cytometry. The proportion of S and G2/M
period frequency of Eca-109 cell transfected with vetor (pRNAT-U6.1/Neo-siSTAT5)
was significantly decreased (*p< 0.05). The proportion of G0/G1 period frequency
was significantly increased (*p < 0.05).dimerize, translocate to the nucleus and bind DNA, initiat-
ing the transcription of target genes. STAT proteins medi-
ate cell growth, differentiation, apoptosis, transformation,
and other functions. In cancer cells, STAT5 activation lead
to the increased expression of downstream target genes
(Bcl-xL, mcL-1, cyclinD1 /D2 and c-myc), which increased
cell proliferation, cell survival, angiogenesis, and immune
system evasion [17]. STAT5 is very mportant in STATs
family, including STAT5a and STAT5b, which plays an im-
portant role in many cancers [18].
The study designed and constructed the siRNA vector
(pRNAT-U6.1/Neo -siSTAT5) aiming to STAT5. Then it
was transfected into Eca-109 cells. The result of RT-PCR
and Western-blot demonstrated STAT5 was significantly
suppressed, not only the mRNA expression, but also the
protein expression, The Bcl-2 and Cyclin D1 expression
in Eca-109 cells transfected with STAT5 siRNA vector
were significantly decreased. The result of MTT demon-






of cells per field
STAT5 siRNA pRNAT-U6.1/
Neo -siSTAT5
13.38 ± 1.87* 24.2 ± 5.1*
siRNA control pRNAT-U6.1/
Neo-siCon
4.76 ± 0.69 65.2 ± 10.4
The blank
control
- 4.49 ± 0.73 71.9 ± 12.4
The average apoptosis rate of Eca-109 cell transfected with STAT5 siRNA was
significantly increased (*p < 0.05), The average amount of cells penetrating
Matrigel was significantly suppressed (*p < 0.05).
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S and G2/M period frequency was significantly de-
creased (p < 0.05). The proportion of G0/G1 period fre-
quency was significantly increased (p < 0.05). Zhao
Zhengjun e.tal approved silencing the STAT5 of liver
carcinoma cell SMMC27721 induced the cell apoptosis,
using siRNA [19]. Duan zhao e.tal approved silencing
the STAT5 depressed the proliferation of cervical carcin-
oma cell HeLa and induced the cell apoptosis [20]. The
proportion of S and G2/M period frequency was signifi-
cantly decreased. The proportion of G0/G1 period fre-
quency was significantly increased. All are associated
with our study. There are other risk factors associated
with esophageal carcinomas. Fascin induces membrane
protrusions and cell motility [21]. Fascin overexpression
plays a role in tumor growth and progression in ESCC
and that cell death caused by its downregulation might
be induced by cell adhesion loss [22]. This indicates that
targeting fascin pathway could be a novel therapeutic
strategy for the human ESCC. ATP-binding cassette sub-
family G member 2 (ABCG2) is a protein that in
humans is encoded by the ABCG2 gene. ABCG2 partici-
pates in efflux of many chemotherapeutic agents [23].
ABCG2 is often expressed in hematopoietic progenitor
or stem cells. Vacuolar-H + −ATPase (V-ATPase) plays a
key role in adjusting and maintaining intracellular pH
and in regulating the drug tolerance of cells [24]. Both
ABCG2 and V-ATPase were over-expressed in esopha-
geal squamous cancer cells. Their expression was associ-
ated with pathological grade, TNM stage and tumor
metastasis in esophageal squamous cancer cells [25].
ABCG2 and V-ATPase expression may be strongly asso-
ciated with drug resistance and tumor metastasis. All
the risk factors were very important in the occurrence
and development of esophageal carcinomas.
The study first approved silencing the STAT5 of
esophageal carcinoma cell line Eca-109 induced the
apoptosis and supressed the proliferation,invasion and
metastasis, which indicated STAT5 might be a novel
therapeutic strategy for the human ESCC.
Conclusions
STAT5 silenced by siRNA could induce the apoptosis,
suppress the proliferation、invasion and metastasis of
esophageal carcinoma cell line Eca-109, which indicated
STAT5 might be a novel therapeutic strategy for the hu-
man ESCC.
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